# (PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer

> **NIH NIH R01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $89,140

## Abstract

Project Summary
This is an application for a Research Supplement to Promote Diversity in Health-Related Research (PA-18-906).
The parent R01 project associated with this application is entitled “(PQ9) Developing EZH2 Degraders for
Treating Triple-Negative Breast Cancer” supported by NCI (5R01CA230854-02). Brandon Dale is the diversity
candidate. He is a US citizen of African-American descent and is currently an MD/PhD graduate student at
Icahn School of Medicine at Mount Sinai, New York. The main goal of this study is to characterize a set of EZH2
degraders in triple-negative breast cancer cellular models.

## Key facts

- **NIH application ID:** 10152794
- **Project number:** 3R01CA230854-03S1
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Jian Jin
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $89,140
- **Award type:** 3
- **Project period:** 2018-09-10 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10152794

## Citation

> US National Institutes of Health, RePORTER application 10152794, (PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer (3R01CA230854-03S1). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10152794. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*